Bragar Eagel & Squire, P.C. Reminds Gossamer Investors that a Class Action Lawsuit Has Been Filed Against Gossamer Bio, Inc. (NASDAQ:GOSS) and Encourages Investors with Large Losses to Contact the Firm

A class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) for allegedly providing materially false and misleading statements regarding its Phase 3 PROSERA study for pulmonary arterial hypertension treatment. The company is accused of expressing confidence in the trial design while concealing material adverse facts about study design, particularly regarding placebo response control at Latin American testing sites. Investors who purchased securities between June 16, 2025, and February 20, 2026, may be eligible to participate in the lawsuit.